Skip to main content

Table 2 BNP and NT-proBNP levels, expressed as median (IQR) during treatment with placebo or linagliptin

From: DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

  Placebo Linagliptin Placebo-subtracted change
Pre Post Change Pre Post Change
BNP
 All 22.9
(10.0–42.8)
21.3
(10.0–52.6)
0.0
(−0.9 to 15.2)
19.6
(10.0–44.3)
22.6
(10.0–39.3)
0.0
(−2.7 to 7.8)
0.0
(−19.0 to 1.7)
 No CKD 11.4
(10.0–23.3)
11.9
(10.0–29.5)
0.0
(−0.9 to 0.3)
10.6
(10.0–21.8)
12.5
(10.0–27.4)
0.0
(0.0–4.6)
0.0
(−1.0 to 1.2)
 CKD 38.5
(26.8–80.3)
56.3
(24.6–107.1)
7.3
(−0.7 to 26.0)
44.2
(20.3–129.0)
37.4
(25.0–78.9)
0.0
(−9.5 to 12.1)
−17.6
(−46.8 to 0.8)
NT-proBNP 
 All 101.0
(36.5–314.5)
122.0
(38.0–267.0)
2.0
(−32.0 to 30.5)
101.0
(44.0–299.0)
78.0
(36.0–272.0)
−3.5
(−27.5 to 19.3)
−19.5
(−62.3 to 19.3)
 No CKD 46.0
(26.0–101.0)
57.0
(20.0–167.0)
0.0
(−12.0 to 20.0)
51.0
(28.5–121.5)
41.0
(26.5–99.0)
3.0
(−17.5 to 17.3)
−2.5
(−35.0 to 15.8)
 CKD 218.5
(108.8–554.8)
261.0
(130.0–696.5)
4.5
(−57.8 to 109.3)
238.5
(107.5–611.5)
184.0
(109.0–483.0)
−17.0*
(−59.3 to 23.0)
−50.0#
(−101.5 to 18.0)
  1. * Significantly different from placebo treatment (p < 0.05 at paired t test on log-transformed data or Mann–Whitney test)
  2. # Significantly different from zero